Oxford BioDynamics launches its Checkpoint Inhibitor response test in the US
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Study to evaluate effectiveness of hypoglossal nerve stimulation
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Guy Villax was also involved with the EFCG and Rx-360 associations and contributed to legislation being passed on both sides of the Atlantic to fight fake medicines and to level the playing field for GMP manufacturing.
Subscribe To Our Newsletter & Stay Updated